Skip to main content
OpenTrials
Completed

NCT Number: NCT04158076

Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine

The purpose of this study is to evaluate the efficacy and safety of co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine in patients with primary hypercholesterolemia and essential hypertension.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypercholesterolemia Cardiovascular Diseases Dyslipidemias Hyperlipidemias Hypertension Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases Vascular Diseases

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Seoul National University Hospital

Seoul, South Korea

About this study

This trial is a phase 3 study to evaluate efficacy and safety of co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine in patients with primary hypercholesterolemia and essential hypertension.

In "Rosuvastatin/Ezetimibe+Telmisartan/Amlodipine" treatment group, 48 subjects will be assigned and the subjects administer "Rosuvastatin/Ezetimibe+Telmisartan/Amlodipine" for 8 weeks.

In "Rosuvastatin/Ezetimibe +Telmisartan " treatment group, 48 subjects will be assigned and the subjects administer "Rosuvastatin/Ezetimibe+Telmisartan" for 8 weeks.

In "Telmisartan/Amlodipine" treatment group, 48 subjects will be assigned and the subjects administer "Telmisartan/Amlodipine" for 8 weeks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent
  • Subjects with hypertension and hyperlipidemia

Exclusion criteria

  • Patient with known or suspected secondary hypertension
  • Other exclusions applied

Treatment and study plan

Ezetimibe/Rosuvastatin

Drug

PO, Once daily(QD), 8weeks

Other names: Rosuvamibe Tab.

Telmisartan

Drug

PO, Once daily(QD), 8weeks

Other names: Micardis Tab.

Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET

Drug

PO, Once daily(QD), 8weeks

Other names: Twynsta

Primary outcomes

  1. Low density lipoprotein cholesterol (LDL-C)

    Time frame: Baseline, Week 8

    LDL-C change at Week 8 compared AD-2071 + AD-2073 with AD-2073

  2. Mean sitting systolic blood pressure (MSSBP)

    Time frame: Baseline, Week 8

    MSSBP change at Week 8 compared AD-2071 + AD-2072 with AD-2071 + AD-2073

Sponsors and collaborators

Lead sponsor

Addpharma Inc.

Industry

Registry information

Official study title

A Randomized, Double-blind, Active-controlled, Multicenter Phase III Trial to Evaluate the Efficacy and Safety of Co-administrated AD-2071 and AD-2073 in Patients With Primary Hypercholesterolemia and Essential Hypertension

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Nov 8, 2019
Registry last updated
May 12, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.